Travelers encouraged to protect themselves from carbon monoxide following recent tragedies
The threat of carbon monoxide has been linked to several recent tragedies involving travelers.
14-year-old Miller Gardner, son of former New York Yankees player Brett Gardner, died on a family vacation at a Costa Rica beach resort back in March.
His death happened one month after three young women from Revere were discovered dead in their Belize hotel room.
Authorities said carbon monoxide poisoning caused the deaths in both cases.
'It's not something that we normally see or talk about which is why it's easy to lose track of it,' said Charon McNabb, President of the National Carbon Monoxide Awareness Association.
McNabb has made it her mission to educate travelers on the steps they can take to protect themselves from carbon monoxide poisoning.
'Call ahead, and ask the management, is it possible to have a carbon monoxide alarm? When was the last time the alarm was checked?,' she advised.
McNabb also recommends avoiding stay near the hotel's pool where equipment is often a hotspot for CO leaks.
'If you have small kids I know it's really enticing to have a room next to the pool, but it could be quite dangerous,' she explained.
Rental platforms like Airbnb and VRBO often indicate whether rentals have carbon monoxide alarms installed.
McNabb said even if your accommodation has a carbon monoxide detector, it won't matter if it isn't tested regularly and replaced every few years.
'Carbon monoxide alarms have a 5-to-10-year shelf life. It's very difficult to tell from the front of an alarm how long into the aging process that alarm might be,' said McNabb.
Safe Kids Worldwide suggests families bring a portable carbon monoxide alarm on vacation especially if the location is an older building.
If a carbon monoxide is already present, the organization suggests testing it out.
Boston 25 News found portable CO detectors with good reviews for under $50 on Amazon.
It's important make sure the device you select is certified as meeting standards set by UL Standards & Engagement.
'People can protect themselves by bringing these small devices with them particularly if you have families. Small children and pets are affected as well,' said Dr. Barbarajean Magnani, Professor of Anatomic and Clinical Pathology Emerita at Tufts University School of Medicine.
Dr. Magnani said carbon monoxide can suffocate victims before they know it's too late.
'The problem with carbon monoxide, it's a colorless, odorless and tasteless gas, so people are unaware if there's a problem, if there's a leak,' she said.
Carbon is the leading cause of poisoning deaths in the U.S.
Symptoms may include:
Headache
Dizziness
Nausea
Vomiting
Weakness
Chest pain
Confusion
According to the Centers for Disease Control and Prevention, more than 400 Americans die each year 'from unintentional carbon monoxide poisoning not linked to fires.'
Data from the National Fire Incident Reporting System shows firefighters responded to more than 4,000 carbon monoxide incidents at hotels, motels, and resorts between 1999 and 2020.
More than 1,000 people have been hurt and at least two dozen have died.
The National Conference of State Legislatures says the requirements for carbon monoxide detectors in homes and hotels differ by state.
Not all U.S. states require properties to install CO detectors.
In 2005, Massachusetts passed 'Nicole's Law' which requires that carbon monoxide detectors be installed in all residences that have any source of carbon monoxide.
'It's important for our government officials to recognize the gap in the safety net and try to close that up for our travelers,' added McNabb.
McNabb is working with lawmakers to advocate for 'Safe Stay Act' which will be introduced in June.
The federal bill would require all hotels and motels nationwide to install compliant carbon monoxide detectors and provide written notice of compliance to guests during check-in.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
19 minutes ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
Yahoo
22 minutes ago
- Yahoo
Eli Lilly hikes UK price of blockbuster weight loss drug Mounjaro by up to 170%
Drugmaker Eli Lilly said it will raise the price of its blockbuster weight loss drug by up to 170 per cent for customers in the United Kingdom. The US pharmaceutical giant confirmed to Euronews Health that effective September 1, the highest dose of Mounjaro will cost £330 for a month's supply, up from £122 currently. The new price is the list price, or what private providers will pay for the drug. Clinics are expected to raise their prices for patients as a result. The price hike is not expected to affect access for patients who receive Mounjaro through the National Health Service (NHS), a spokesperson for NHS England said. 'The approved list price increase will not affect NHS commissioning of [Mounjaro] in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes,' the spokesperson told Euronews Health. Related Eli Lilly will seek approval for experimental weight loss pill after promising study The NHS England spokesperson said patients who get the drug through private doctors should contact their providers. A Lilly spokesperson said the company will work with private doctors to "maintain patient access'. Mounjaro is used to treat obesity, type 2 diabetes, and weight-related health problems in both the UK and the European Union. Rival weight loss jabs Ozempic and Wegovy, made by Danish drugmaker Novo Nordisk, are also available. A Lilly spokesperson said the increase aims to bring Mounjaro's UK price closer to what is paid in other European countries. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability,' the spokesperson said. 'With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation'. The move comes as US President Donald Trump puts pressure on pharmaceutical companies to lower drug costs for Americans to a level that matches the lowest price offered in other wealthy countries. Related Portugal tightens rules on weight loss drug prescriptions to prevent misuse In May, Trump complained that a 'friend' of his paid significantly less for 'the fat shot' in the UK than in the United States. He later accused European countries of 'freeloading,' saying Americans pay higher prices to cover the cost of new drug development while other wealthy countries benefit. Since then, some drug companies have signaled they will attempt to align prices paid in the US and other countries. The Lilly spokesperson said the Mounjaro price increase will 'address pricing inconsistencies compared to other developed countries, including in Europe'.
Yahoo
35 minutes ago
- Yahoo
'Legally binding' dye agreement with WK Kellogg lauded by Texas attorney general
WK Kellogg has entered a legally binding agreement to remove 'toxic dyes' from its breakfast cereals, according to Texas Attorney General Ken Paxton. Paxton said in a statement shared by his office yesterday (13 August) that he has 'signed a historic Assurance of Voluntary Compliance' agreement with WK Kellogg, which, he added, 'certifies that the company is legally agreeing to remove artificial food colourings from its cereals by the end of 2027'. Under a transparency commitment on the WK Kellogg website, the company says 85% of its cereals contain no FD&C colours and none contain the Red No. 3 dye. Reformulations to remove all FD&C colours in cereals served in schools will be completed by 2026-27, the company says, adding: 'We will remove FD&C colours from the small percentage of our foods in retail that contain them' by the end of 2027. However, the pledges are not legally binding. Just Food has asked WK Kellogg to comment on the Paxton statement. WK Kellogg responded, repeating the pledges made in the online transparency commitment. However, the company added: 'We appreciate the opportunity to work collaboratively with the Texas AG's office and share their focus on health and wellness. We see the growing focus on health as an opportunity to meet consumer needs in even more meaningful ways.' The attorney general launched an investigation in April into WK Kellogg's claims that its cereals are 'healthy'. Paxton had suggested the products 'are filled with petroleum-based artificial food colourings' that have been linked to health issues such as hyperactivity, obesity, autoimmune disorders, hormonal imbalances, and cancer. And he claimed some of WK Kellogg's products 'specifically contain' artificial food dyes in shades of blue, red, yellow, green and orange. Yesterday, Paxton lauded the development with WK Kellogg as a 'historic legal agreement with a major food company', which, he said, 'represents a significant milestone in the movement to remove toxic dyes from foods and protect the health of all Americans'. He added: 'While other companies have verbally committed to removing food dyes, Kellogg's is the first to officially sign a legally binding agreement confirming that it will remove food colourings.' Since President Trump took office, US Health Secretary Robert F. Kennedy Jr. has launched a campaign – under his Make America Healthy Again (MAHA) initiative - to urge major food manufacturers to phase out the use of artificial dyes. Many have since made pledges to do that but under their own auspices, including Kraft Heinz and General Mills. In January, the US Food and Drug Administration (FDA) said it planned to ban the use of the Red 3 food colouring additive in food, supplements and ingestible drugs. Then in April, the FDA unveiled measures to phase out the use of petroleum-based food dyes by the end of next year, followed by the approval in May for the use of three natural colour additives. Paxton applauded WK Kellogg 'for doing the right thing' and urged 'other food manufacturers to sign similar agreements to demonstrate their commitment to helping Americans live healthier lives'. Meanwhile, markets await news of the progress in Ferrero's takeover of WK Kellogg. The confectionery giant entered an agreement in July to acquire the business for $3.1bn, with the deal expected to close in the current second half of this year. However, it needs to be signed off by regulators and WK Kellogg's shareholders. "'Legally binding' dye agreement with WK Kellogg lauded by Texas attorney general" was originally created and published by Just Food, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
